Dren Bio, Inc.

Dren Bio, Inc. is a biopharmaceutical company focused on developing innovative antibody therapeutics that target and deplete pathogenic cells, primarily for oncology and autoimmune disease treatments. Founded in 2019 and headquartered in Foster City, US, Dren Bio develops antibody therapeutics aimed at treating various diseases. The company has successfully raised a total of USD 62.

5 mn through its Series B funding round in March 2022, which was co-led by Aisling Capital and HBM Partners. Founders John Wesley and Nenad Tomasevic are backed by a strong history in the biotech sector, contributing to the company's strategic growth. Dren Bio has completed four deals to date, with its latest round of funding attracting prominent investors including Pfizer Inc. and Alexandria Venture Investments.

Dren Bio specializes in creating innovative antibody therapeutics targeting pathogenic cells and disease-causing agents. Its main offerings include two first-in-class clinical-stage programs in oncology and autoimmune diseases, supported by its proprietary Targeted Myeloid Engager and Phagocytosis Platform. These products aim to enhance the immune system's efficacy in eliminating harmful cells, catering primarily to patients with cancer and serious autoimmune conditions, as well as healthcare institutions. Dren Bio's revenue generation is founded on collaborations with healthcare organizations and research institutions, primarily through licensing agreements and milestone payments linked to clinical development.

Although specific revenue figures are not publicly available, the company’s business strategy focuses on partnerships that facilitate the advancement and commercialization of its therapeutic products, which may include direct sales or distribution through specialized channels. Dren Bio plans to leverage its recent Series B funding of USD 62. 5 mn to advance its internal pipeline utilizing the Targeted Myeloid Engager and Phagocytosis platform. The company is also focused on expanding its market reach into North America, Europe, and select regions in Asia by 2023, targeting areas with significant unmet medical needs.

Additionally, the company continues to develop its innovative therapeutic products aimed at addressing critical healthcare challenges.